GSA Capital Partners LLP boosted its stake in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA – Get Rating) by 186.4% during the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 117,109 shares of the company's stock after buying an additional 76,224 shares during the period. GSA Capital Partners LLP owned approximately 0.29% of Taysha Gene Therapies worth $764,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently bought and sold shares of TSHA. ProShare Advisors LLC bought a new position in shares of Taysha Gene Therapies during the 4th quarter worth $121,000. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. bought a new position in shares of Taysha Gene Therapies during the 4th quarter worth $259,000. Swiss National Bank grew its position in shares of Taysha Gene Therapies by 9.3% during the 1st quarter. Swiss National Bank now owns 41,000 shares of the company's stock worth $267,000 after buying an additional 3,500 shares in the last quarter. TimesSquare Capital Management LLC grew its position in shares of Taysha Gene Therapies by 1.0% during the 1st quarter. TimesSquare Capital Management LLC now owns 665,900 shares of the company's stock worth $4,342,000 after buying an additional 6,800 shares in the last quarter. Finally, Sargent Investment Group LLC bought a new position in shares of Taysha Gene Therapies during the 1st quarter worth $69,000. Hedge funds and other institutional investors own 46.05% of the company's stock.
Get Taysha Gene Therapies alerts:Wall Street Analysts Forecast Growth
A number of equities research analysts recently weighed in on the company. Chardan Capital dropped their price objective on Taysha Gene Therapies from $34.00 to $32.00 and set a "buy" rating on the stock in a research report on Friday, August 12th. Guggenheim reduced their price objective on Taysha Gene Therapies to $22.00 and set a "na" rating for the company in a research note on Tuesday, May 17th. The Goldman Sachs Group reduced their price objective on Taysha Gene Therapies from $27.00 to $16.00 and set a "buy" rating for the company in a research note on Tuesday, May 24th. Wedbush reduced their price objective on Taysha Gene Therapies from $9.00 to $5.00 and set an "outperform" rating for the company in a research note on Friday, August 12th. Finally, Needham & Company LLC reduced their price objective on Taysha Gene Therapies to $20.00 and set a "buy" rating for the company in a research note on Tuesday, May 17th. Eleven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Taysha Gene Therapies has an average rating of "Buy" and an average price target of $26.00.
Taysha Gene Therapies Stock Down 3.6 %
Taysha Gene Therapies stock opened at $3.74 on Monday. The stock has a market capitalization of $153.69 million, a PE ratio of -0.78 and a beta of 0.99. Taysha Gene Therapies, Inc. has a 12 month low of $2.33 and a 12 month high of $21.90. The business has a 50 day simple moving average of $4.00 and a 200-day simple moving average of $4.77. The company has a debt-to-equity ratio of 1.15, a current ratio of 1.79 and a quick ratio of 1.79.Insider Transactions at Taysha Gene Therapies
In other news, CMO Suyash Prasad sold 23,923 shares of Taysha Gene Therapies stock in a transaction that occurred on Friday, July 1st. The stock was sold at an average price of $3.53, for a total value of $84,448.19. Following the sale, the chief marketing officer now directly owns 543,450 shares of the company's stock, valued at $1,918,378.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold 40,152 shares of company stock valued at $145,109 over the last ninety days. Insiders own 42.40% of the company's stock.
Taysha Gene Therapies Profile
(Get Rating)
Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis.
Recommended Stories
- Get a free copy of the StockNews.com research report on Taysha Gene Therapies (TSHA)
- 2 EV Suppliers Powering To Gains After Raising Views
- Applied Materials Results Show A Slowing Semiconductor Market
- MarketBeat: Week in Review 8/15 – 8/19
- Apple's Stock Could Be On The Verge Of Another 30% Rally
- Near-Term Headwinds Present An Opportunity In Ross Stores
Want to see what other hedge funds are holding TSHA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Taysha Gene Therapies, Inc. (NASDAQ:TSHA – Get Rating).
Receive News & Ratings for Taysha Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taysha Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.